Buy MAP Pharmaceutical For 70% Upside

Healthcare Sector and Stocks Analysis from Seeking Alpha

Mon, 26 Nov 2012

By Stock Whisper : MAP Pharmaceuticals ( MAPP ) saw an appreciation of 20% on Friday. We believe this is just the start of an epic run for MAPP shareholders. The company's application for LEVADEX was rejected by FDA back in March due to CMC issues and no objections were made on efficacy or safety. ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Topics:

Content Partners

Site Directory Site Map Our Products

Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News

International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland

Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.